


Amendments to the Claims:

The following Listing of Claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (Currently amended) A pharmaceutical aerosol formulation comprising particles of formoterol or a pharmaceutically acceptable salt, ~~or solvate or physiologically functional derivative thereof~~, said particles being suspended in the formulation; ~~a compound of the formula (I):~~



~~in which: R₁ is 1-butyl, 2-butyl, cyclohexyl or phenyl and R₂ is acetyl or isobutanoyl, said compound of formula (I) being ciclesonide dissolved in the formulation; and~~

a propellant selected from 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof.

2. (Original) A pharmaceutical aerosol formulation according to claim 1, wherein the formoterol is in the form of fomoterol fumarate.
3. (Canceled) ~~A pharmaceutical aerosol formulation according to claim 1, wherein the compound of formula (I) is ciclesonide.~~
4. (Previously Presented) A pharmaceutical aerosol formulation according to claim 1, wherein the formulation further comprises ethanol.
5. (Original) A pharmaceutical aerosol formulation according to claim 4, wherein ethanol is present in an amount from 3 to 20% by weight of the formulation.

6. (Original) A pharmaceutical aerosol formulation according to claim 5, wherein ethanol is present in an amount from 3.5 to 20% by weight of the formulation.
7. (Original) A pharmaceutical aerosol formulation according to claim 6, wherein ethanol is present in an amount from 5 to 20% by weight of the formulation.
8. ~~(canceled) A pharmaceutical aerosol formulation according to claim 1, wherein the propellant is 1,1,1,2-tetrafluoroethane or a mixture of 1,1,1,2-tetrafluoroethane and 1,1,1,2,3,3,3-heptafluoropropane.~~
9. (Previously Presented) A pharmaceutical aerosol formulation according to claim 1, wherein 1,1,1,2-tetrafluoroethane is the only propellant component.
10. (Previously Presented) A pharmaceutical aerosol formulation according to claim 1, wherein the formulation further comprises a bulking agent having a mass median diameter of less than one micron.
11. (Original) A pharmaceutical aerosol formulation according to claim 10, wherein the bulking agent has a mass median diameter of not more than 300 nm.
12. ~~(currently amended) A pharmaceutical aerosol formulation according to claim 10, wherein the weight ratio of formoterol or a pharmaceutically acceptable salt, or solvate or physiologically functional derivative thereof to bulking agent is in the range 1:0.1 to 1:25.~~
13. (Previously Presented) A dispenser comprising an aerosol vial equipped with a dispensing valve, said aerosol vial containing a formulation according to claim 1.
14. (Original) A dispenser according to claim 13, wherein an interior surface of the aerosol vial is coated with a coating comprising a fluorocarbon polymer.
15. ~~(currently amended) A method of preparing a formulation according to claim 1, the method comprising the steps of (i) providing a solution of ciclesonide the compound of formula (I) in 1,1,1,2-tetrafluoroethane and/or 1,1,1,2,3,3,3-heptafluoropropane and (ii) dispersing particles of formoterol or a pharmaceutically acceptable salt or solvate thereof.~~

